RecruitingNCT04119713

Autoimmunity After Checkpoint Blockade

Mechanisms of Immunotoxicology in Cancer Patients

Sponsor

Abramson Cancer Center at Penn Medicine

Enrollment

600 participants

Start Date

Feb 24, 2020

Study Type

OBSERVATIONAL

Conditions

autoimmunity Cancer Oncology Immunotoxicity

Summary

The purpose of this study is to better understand how the treatment of cancer with immune checkpoint inhibitors (ICI) leads to the development of autoimmunity. Specifically, we wish to understand the genetics and immune system features that cause a subset of cancer patients treated with checkpoint inhibitor therapy to develop an immune-related adverse event (irAE).

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a new treatment for people with cancer, immunotoxicity, and other related conditions. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.